2,3,4,5-四氢-1H-1,4-苯并二氮杂-3-酮 | 168080-43-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2,3,4,5-四氢-1H-1,4-苯并二氮杂-3-酮
• 中文别名: 1,2,4,5-四氢苯并[E][1,4]二氮杂草-3-酮；1,2,4,5-四氢苯并[e][1,4]二氮杂草-3-酮
• 英文名称: 2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-3-one
• 英文别名: 1,2,4,5-tetrahydrobenzo[e]-1,4-diazepin-3-one；1,2,4,5-Tetrahydro-benzo[e][1,4]diazepin-3-one；1,2,4,5-tetrahydro-1,4-benzodiazepin-3-one
• CAS: 168080-43-1
• 化学式: C₉H₁₀N₂O
• mdl: MFCD07784140
• 分子量: 162.191
• InChiKey: YDCUQJVYYWANPZ-UHFFFAOYSA-N

物化性质

• 熔点：
  174-176°C
• 溶解度：
  DMSO（少许）、甲醇（少许）、

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

制备方法与用途

这些化合物对ARGinine vasopressin受体2型（V2受体）具有刺激活性，可用作抗尿崩症、夜间多尿、夜间遗尿、膀胱过度活动症、血友病或von Willebrand病的预防或治疗剂。

反应信息

• 作为反应物：
  描述：

  2,3,4,5-四氢-1H-1,4-苯并二氮杂-3-酮 、 溴乙酸乙酯 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 ethyl (3-oxo-1,2,3,5-tetrahydrobenzo[e]-1,4-diazepin-4-yl)acetate
  参考文献：
  名称：

  AROMATIC AMIDE DERIVATIVES, MEDICINAL COMPOSITIONS CONTAINING THE SAME, MEDICAL USES OF BOTH

  摘要：

  本发明提供了具有V2受体激动作用的芳香酰胺衍生物，可用作治疗或预防尿崩症、夜尿症、夜间遗尿、膀胱过度活跃或类似疾病的药物，并由通式（I）表示： 其中R1代表氢原子或可能具有取代基的C1-6烷基基团，R2是氢原子或C1-6烷基基团，R3是氢原子、C1-6烷基基团或类似物，R4、R5和R6独立地是氢原子、卤原子或类似物，R7是氢原子、可能具有取代基的杂环基团、C3-8环烷基团、可能具有取代基的氨基团或可能具有取代基的C1-6烷氧基团；M1是单键、C1-4烷基烃基团或类似物，Y是N或CRF（在该式中，RF代表氢原子、C1-6烷基基团或类似物），或其药学上可接受的盐，或其前药，或包含其的药物组合物和药物用途。

  公开号：

  EP1813603A1

文献信息

• [EN] INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5), PHARMACEUTICAL PRODUCTS THEREOF, AND METHODS THEREOF<br/>[FR] INHIBITEURS DE PROTÉINE ARGININE MÉTHYLTRANSFÉRASE 5 (PRMT5), LEURS PRODUITS PHARMACEUTIQUES ET PROCÉDÉS ASSOCIÉS
  申请人：PHARMABLOCK SCIENCES NANJING INC

  公开号：WO2019173804A1

  公开（公告）日：2019-09-12

  The present invention provides PRMT5 inhibitors of Formula (I), wherein R1 is a non-hydrogen monovalent group; W is a direct bond or -NH-; T, U, and V are independently of each other selected from C and N; R2 is H or a halo; m is 1 or 2; X is a carbon, a nitrogen, or an oxygen; Y is C or N; Z is a direct bond or a carbon; R3 is H, a non-hydrogen monovalent group, an oxo group, a bivalent spiro ring-forming group, or a bivalent bridge-forming group; n is 1 or 2; and Formula (II) stands for a single bond or a double bond. Pharmaceutical products comprising the PRMT5 inhibitors and use thereof in treating proliferative disorders such as cancer, metabolic disorders, blood disorders, autoimmune diseases, and inflammatory diseases are also provided.

  本发明提供了式（I）的PRMT5抑制剂，其中R1是非氢单价基团；W是直键或-NH-；T、U和V分别独立地选自C和N；R2是H或卤素；m为1或2；X是碳、氮或氧；Y是C或N；Z是直键或碳；R3是H、非氢单价基团、氧基团、二价螺环形成基团或二价桥形成基团；n为1或2；式（II）代表单键或双键。还提供了包含PRMT5抑制剂的药物产品以及在治疗增殖性疾病如癌症、代谢性疾病、血液疾病、自身免疫疾病和炎症性疾病中使用它们的用途。
• FUSED HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS
  申请人：Shigeta Yukihiro

  公开号：US20120209005A1

  公开（公告）日：2012-08-16

  Fused heterocyclic compounds useful for prevention, treatment or improvement of diseases against which activation of the thrombopoietin receptor is effective are provided. A compound represented by the formula (I) (wherein R 1 is an aryl group fused to a saturated ring or the like, A, B, L 1 , R 2 , L 2 , L 3 , Y, L 4 , R 3 and X are defined in the description), a tautomer, prodrug or a pharmaceutically acceptable salt of the compound or a solvate thereof.

  提供了对激活血小板生成素受体有效的疾病的预防、治疗或改善有用的融合杂环化合物。代表式(I)的化合物（其中R1是与饱和环或类似物融合的芳基，A、B、L1、R2、L2、L3、Y、L4、R3和X在描述中有定义），该化合物的互变异构体、前药或药用可接受的盐或其溶剂化物。
• Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both
  申请人：Yokoyama Kenji

  公开号：US20070232594A1

  公开（公告）日：2007-10-04

  A present invention provides aromatic amide derivatives which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like, and are represented by the general formula (I): wherein R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group; M 1 is a single bond, a C 1-4 alkylene group or the like Y is N or CR F (in the formula, R F represents a hydrogen atom, a C 1-6 alkyl group or the like or a pharmaceutically acceptable salt thereof, or a prodrug thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  本发明提供了具有V2受体激动作用的芳香酰胺衍生物，可用作治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等药物，其通式表示为（I）：其中R1表示氢原子或C1-6烷基，可以有取代基，R2表示氢原子或C1-6烷基，R3表示氢原子、C1-6烷基或类似物，R4、R5和R6分别表示氢原子、卤原子或类似物，R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或C1-6烷氧基；M1表示单键、C1-4烷基等，Y表示N或CRF（在公式中，RF表示氢原子、C1-6烷基或类似物的药物可接受的盐，或其前药，或包含它的制药组合物和制药用途）。
• Urea derivative, medicinal composition containing the same, and medicinal use of these
  申请人：Suzuki Ritsu

  公开号：US20080161294A1

  公开（公告）日：2008-07-03

  Urea derivatives represented by the following general formula (I): which have an agonism of V2 receptor, are useful as agents for the treatment or prevention of diabetes insipidus, nocturia, nocturnal enuresis, overactive bladder or the like. In the formula, R 1 represents a hydrogen atom or a C 1-6 alkyl group which may have a substituent, R 2 is a hydrogen atom or a C 1-6 alkyl group, R 3 is a hydrogen atom, a C 1-6 alkyl group or the like, R 4 , R 5 and R 6 are independently a hydrogen atom, a halogen atom or the like, R 7 is a hydrogen atom, a heteroaryl group which may have a substituent, a C 3-8 cycloalkyl group, an amino group which may have a substituent or a C 1-6 alkoxy group which may have a substituted group, M 1 is a single bond, a C 1-4 alkylene group or the like, Y is N or CR F (in the formula, and R F represents a hydrogen atom, a C 1-6 alkyl group or the like, or pharmaceutically acceptable salts thereof, or prodrugs thereof, or pharmaceutical compositions comprising the same and pharmaceutical uses thereof.

  以下通式（I）所表示的尿素衍生物具有V2受体激动剂作用，可用于治疗或预防尿崩症、夜尿症、夜间遗尿、过度活动膀胱等疾病。在该通式中，R1表示氢原子或C1-6烷基，可以有取代基；R2表示氢原子或C1-6烷基；R3表示氢原子、C1-6烷基或类似物；R4、R5和R6独立地表示氢原子、卤素原子或类似物；R7表示氢原子、可以有取代基的杂环芳基、C3-8环烷基、可以有取代基的氨基或可以有取代基的C1-6烷氧基；M1表示单键、C1-4烷基等；Y表示N或CRF（在该式中，RF表示氢原子、C1-6烷基或类似物）；以及其药学上可接受的盐、前药或包含它们的制剂，以及其医药用途。
• Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
  申请人：Pharmacia Corporation

  公开号：US20040127470A1

  公开（公告）日：2004-07-01

  The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.

  本发明涉及一种新型的预防和/或治疗肿瘤疾病的方法，通过向需要此类预防或治疗的受试者施用至少一种Cox-2抑制剂与EGF受体拮抗剂的组合物来实现。同时还描述了组合物、制药组合物和试剂盒。